[{"path":"_pages/404.md","url":"/404.html","title":"Page Not Found","fields":{ "title":"Page Not Found","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"This page may have moved, or the link may be out of date."},"body":"
I earned my medical degree from Lebanese University in 2023. From 2023 to 2026, I completed a postdoctoral fellowship in genitourinary oncology at Dana-Farber Cancer Institute and Harvard Medical School, mentored by Dr. Toni K. Choueiri. I am now part of the Yale Traditional Internal Medicine Residency Program.
\n
My research has included integrative analyses of circulating and tumor biomarkers in renal cell carcinoma, with work spanning tumor–host interactions, immune evasion, the gut microbiome, and cancer genomics. Selected publications are included below.
\n
From 2006 to 2021, I also studied piano at the Lebanese National Higher Conservatory of Music under the tutelage of Loucine Panjarian, earning a Bachelor’s Degree with High Distinction.
\n\n","media":{"gallery":[]}},{"path":"_pages/admin.html","url":"/admin/","title":"Private editor","fields":{ "title":"Private editor","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"Owner access to site content and page counts."},"body":"\n\n
Sign in with your GitHub account. Content drafts are reviewed before publication.
\n\n","media":{"gallery":[]}},{"path":"_pages/archive-layout-with-content.md","url":"/archive-layout-with-content/","title":"Archive Layout with Content","fields":{ "title":"Archive Layout with Content","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
A variety of common markup showing how the theme styles them.
The abbreviation CSS stands for “Cascading Style Sheets”.
\n\n
Cite Tag
\n\n
“Code is poetry.” —Automattic
\n\n
Code Tag
\n\n
You will learn later on in these tests that word-wrap: break-word; will be your best friend.
\n\n
Strike Tag
\n\n
This tag will let you strikeout text.
\n\n
Emphasize Tag
\n\n
The emphasize tag should italicize text.
\n\n
Insert Tag
\n\n
This tag should denote inserted text.
\n\n
Keyboard Tag
\n\n
This scarcely known tag emulates keyboard text, which is usually styled like the <code> tag.
\n\n
Preformatted Tag
\n\n
This tag styles large blocks of code.
\n\n
\n.post-title {\n margin: 0 0 5px;\n font-weight: bold;\n font-size: 38px;\n line-height: 1.2;\n and here's a line of some really, really, really, really long text, just to see how the PRE tag handles it and to find out how it overflows;\n}\n
\n\n","media":{"gallery":[]}},{"path":"_pages/awards.md","url":"/awards/","title":"Honors & Awards","fields":{ "title":"Honors & Awards","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"Research honors and recognition."},"body":"\n
\n \n
Merit Travel Grant
OncLive National Fellows Forum for Genitourinary Cancers · San Francisco, CA, USA
\n
\n
\n \n
Merit Award
European Society of Medical Oncology (ESMO) Congress · Berlin, Germany
\n
\n
\n \n
Conquer Cancer Merit Award
American Society of Clinical Oncology (ASCO) Annual Meeting · Chicago, IL, USA
\n
\n
\n \n
Conquer Cancer Merit Award
American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium · San Francisco, CA, USA
\n
\n
\n \n
Merit Travel Grant
OncLive National Fellows Forum for Genitourinary Cancers · San Francisco, CA, USA
\n
\n
\n \n
Frank Shaughnessy Endowed Fellowship in Kidney Cancer
Boston, MA, USA
\n
\n
\n \n
Merit Travel Grant
OncLive National Fellows Forum for Genitourinary Cancers · San Francisco, CA, USA
\n
\n
\n \n
Merit Award for Distinguished Medical Students
American Lebanese Medical Association (ALMA) · Beirut, Lebanon
\n
\n\n","media":{"gallery":[]}},{"path":"_pages/category-archive.html","url":"/categories/","title":"Posts by Category","fields":{ "title":"Posts by Category","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n","media":{"gallery":[]}},{"path":"_pages/collection-archive.html","url":"/collection-archive/","title":"Posts by Collection","fields":{ "title":"Posts by Collection","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"\n\n\n\n \n \n \n
Bibliometric analysis evaluating the volume, trends, and global contribution of transplant-related research output from the Arab world between 2005 and 2019.
\n\n \n \n\n \n
Recommended citation: El Ayoubi LM, El Masri J, Machaalani M, El Hage S, Salameh P. Contribution of Arab World in Transplant Research: A PubMed-Based Bibliometric Analysis. Transpl Immunol. 2021;68:101432. doi:10.1016/j.trim.2021.101432. \n View Paper\n
Comprehensive review of repurposed pharmacologic agents as strategies to overcome therapeutic resistance in colorectal cancer.
\n\n \n \n\n \n
Recommended citation: El Zarif T, Yibrin M, De Oliveira-Gomes D, Machaalani M, Nawfal R, Bittar G, Bahmad HF, Bitar N. Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing. Cancers (Basel). 2022;14(9):2105. doi:10.3390/cancers14092105. \n View Paper\n
Published in Vascular Health and Risk Management, 2022
\n\n \n\n \n
\n
Cross-sectional study evaluating hypertension knowledge, attitudes, and clinical practices among hypertensive patients in Lebanon.
\n\n \n \n\n \n
Recommended citation: Machaalani M, Seifeddine H, Ali A, Bitar H, Briman O, Chahine MN. Knowledge, Attitude, and Practice Toward Hypertension Among Hypertensive Patients Residing in Lebanon. Vasc Health Risk Manag. 2022;18:541-553. doi:10.2147/VHRM.S367187. \n View Paper\n
Case-control study assessing cardiovascular disease knowledge, attitudes, and preventive practices among Lebanese adults.
\n\n \n \n\n \n
Recommended citation: Machaalani M, Fakhry B, Zwaideh M, Mendelek K, Mahmoud N, Hammoud T, Chahine MN. Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population. Global Heart. 2022;17(1):47. doi:10.5334/gh.1138. \n View Paper\n
Published in Journal of the Egyptian Public Health Association, 2022
\n\n \n\n \n
\n
Bibliometric evaluation of cancer research productivity across Arab countries between 2005 and 2019.
\n\n \n \n\n \n
Recommended citation: Machaalani M, El Masri J, El Ayoubi LM, Matar B. Cancer research activity in the Arab world: a 15-year bibliometric analysis. J Egypt Public Health Assoc. 2022;97(1):26. doi:10.1186/s42506-022-00120-6. \n View Paper\n
Single-cell and functional immunogenomic analysis identifying progressive tumor-resident NK cell dysfunction as a predictor of poor outcomes in advanced clear-cell renal cell carcinoma.
\n\n \n \n\n \n
Recommended citation: Xu W, Birch G, Melki A, Moritz V, Bharadwaj M, Schindler NR, Labaki C, Saliby RM, Dinh K, Horst JT, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee GS-M, Hurwitz M, McGregor BA, Hirsch MS, Shukla SA, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open. 2025;10(2):104105. doi:10.1016/j.esmoop.2024.104105. \n View Paper\n
Published in Signal Transduction and Targeted Therapy, 2025
\n\n \n\n \n
\n
Comprehensive review of AXL receptor tyrosine kinase signaling, therapeutic targeting strategies, and resistance mechanisms across cancer types.
\n\n \n \n\n \n
Recommended citation: Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L, Machaalani M, Eid M, Singh RP, Choueiri TK, Pal S, Sabarwal A. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct Target Ther. 2025;10(1):37. doi:10.1038/s41392-024-02121-7. \n View Paper\n
Multicenter retrospective cohort study evaluating the safety and clinical outcomes of immune checkpoint inhibitors in patients with preexisting autoimmune neurologic disorders.
\n\n \n \n\n \n
Recommended citation: Fletcher K, Machaalani M, El Hajj Chehade R, Nassar AH, Nawfal R, Manos M, Menzies AM, Aboubakar-Nana F, Hasse JC, Pinato DJ, Johnson A, Olsson-Brown AC, Carlino MS, Malgieri A, Cortellini A, Singh A, Parikh K, Kim SY, Naqash AR, Long GV, Challa P, Choueiri TK, Sharon E, Shah S, Johnson DB. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open. 2025;8(6):e2513727. doi:10.1001/jamanetworkopen.2025.13727. \n View Paper\n
Multi-institutional study evaluating the impact of comorbidity burden on treatment outcomes and adverse events in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor–based combinations.
\n\n \n \n\n \n
Recommended citation: Yekeduz E, Zarba M, Saad E, El Hajj Chehade R, Eid M, Saliby RM, Steiner C, Machaalani M, Nawfal R, Semaan K, Ürün Y, Heng DYC, Choueiri TK. Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2025;23(4):102385. doi:10.1016/j.clgc.2025.102385. \n View Paper\n
Integrated single-cell and immunogenomic analysis defining the immune-depleted tumor microenvironment and impaired antitumor immunity in chromophobe renal cell carcinoma.
\n\n \n \n\n \n
Recommended citation: Labaki C, Saad E, Madsen KN, Hobeika C, Bi K, Alchoueiry M, Camp S, Hou Y, Bakouny Z, Matar S, El Ahmar N, Nyman J, Zhang L, Priolo C, Rout R, Daou M, Khabibullin D, Salem S, Schindler N, Saliby RM, Meli K, Wells C, Pimenta E, Takemura K, Marji J, Eid M, Sarlemi K, Xu J, Denize T, El Hajj Chehade R, Machaalani M, Nawfal R, Khattoun W, Saleh M, El Masri J, Haddad NR, Xu W, McGregor BA, Hirsch MS, Yilmaz R, Cheng DY, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2025;43(23):2639-2654. doi:10.1200/JCO-25-00234. \n View Paper\n
Preclinical study demonstrating that AXL inhibition overcomes c-Met–driven therapeutic resistance in renal cancer and promotes tumor cell death through enhanced oxidative stress.
\n\n \n \n\n \n
Recommended citation: Sabarwal A, Machaalani M, Rawat L, Wedel J, Tabasum S, Sasamoto Y, Buerger F, Ascione J, Eid M, Semaan K, Saad E, Yang Y, Lee D, Hodi FS, Freedman ML, Lee GSM, Balan M, Choueiri TK, Pal S. Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress. Cancer Lett. 2025;633:217984. doi:10.1016/j.canlet.2025.217984. \n View Paper\n
Genomic and immunohistochemical analysis identifying somatic MLH1 deficiency as a rare but robust predictor of exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma.
\n\n \n \n\n \n
Recommended citation: Dawidek MT, Posada Calderon L, Shah PK, Mittal R, Agridag Ucpinar B, Bakouny Z, Meli K, Saad E, Saliby RM, Woo HJ, Khandwala YS, Eid M, Labaki C, Machaalani M, Coleman J, Russo P, Kotecha RR, Carlo MI, Akin O, Braun DA, Choueiri TK, Reznik E, Chen YB, Motzer RJ, Voss MH, Hakimi AA. MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma. Eur Urol. 2025 Nov 4:S0302-2838(25)04721-9. doi: 10.1016/j.eururo.2025.09.4162. Epub ahead of print. PMID: 41193371. \n View Paper\n
Mechanistic study identifying SLC1A1/EAAT3 as an epigenetically regulated metabolic dependency in clear cell renal cell carcinoma that sustains oncogenic metabolism, promotes immune exclusion, and drives metastatic progression.
\n\n \n \n\n \n
Recommended citation: Grubb T, Koochaki P, Matar S, Ghandour F, Machaalani M, Saad E, Tang C, Reznik E, Khatun J, Salem C, Dubasik N, Orlando DA, Guenther MG, Parajuli G, Srivastava RM, Martinez SR, Coker JA, Kotecha RR, Hakimi AA, Asara JM, Chan TA, Vanharanta S, Stauffer SR, Kaelin WG Jr, Signoretti S, Choueiri TK, Chakraborty AA. The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs. Nat Commun. 2025;16(1):10012. doi:10.1038/s41467-025-64983-x. \n View Paper\n
Mechanistic and translational study demonstrating that HIF2-driven PTHLH mediates hypercalcemia and cachexia in clear cell renal cell carcinoma and is rapidly reversed by HIF2 inhibition.
\n\n \n \n\n \n
Recommended citation: Abu-Remaileh M, Stransky LA, Bhalerao N, Shirole NH, Jiang Q, Saad E, Machaalani M, Vigeant SM, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri TK, Pitarresi JR, Carr SA, Udeshi ND, Kaelin WG Jr. Targeting of HIF2-driven cachexia in kidney cancer. Nat Med. 2026 Jan;32(1):245-257. doi: 10.1038/s41591-025-04054-2. Epub 2025 Nov 28. Erratum in: Nat Med. 2026 Feb;32(2):766. doi: 10.1038/s41591-026-04236-6. PMID: 41315757; PMCID: PMC12823431. \n View Paper\n
Evaluation of soluble MAdCAM-1 as a prognostic biomarker in metastatic renal cell carcinoma, linking clinical outcomes to gut microbiota composition and immune regulation across three independent clinical trials.
\n\n \n \n\n \n
Recommended citation: Alves Costa Silva C†, Machaalani M†, Saliby RM†, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, Vernerey D, Lee GS, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Albiges L. Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma. Nature Medicine. 2026. doi:10.1038/s41591-025-04067-x. †Equal contribution. \n View Paper\n
Integrated clinical, genomic, and transcriptomic analysis of renal cell carcinoma with NF2 biallelic loss and merlin protein deficiency, demonstrating an aggressive phenotype characterized by high proliferation, immune dysfunction, frequent cell-cycle and DNA damage–response alterations, and limited benefit from immunotherapy.
\n\n \n \n\n \n
Recommended citation: Yekedüz E, Bian W, Siegmund SE, Machaalani M, El Masri J, Saleh M, Saad E, Ascione L, El Halabi R, Steiner C, Mourad P, Berg SA, McGregor B, Mantia C, Ravi P, Xu W, Hirsch MS, Choueiri TK, Serzan M. Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2. Clinical Cancer Research. 2026. doi:10.1158/1078-0432.CCR-25-2871. \n View Paper\n
Published in Journal of the National Cancer Institute, 2026
\n\n \n\n \n
\n
Comprehensive clinical, genomic, and immune correlates of T-DXd outcomes in advanced breast cancer across two independent institutional cohorts.
\n\n \n \n\n \n
Recommended citation: Nassar AH, Bou Farhat E, Abushukair H, Alchoueiry M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri TK, Rakaee M, Busund LTR, Takabe Y, Lau SF, Rall K, Naqash AR, Jansen C, Wang X, Challa P, Tarantino P, Partridge AH, Tolaney SM, Kwiatkowski DJ, Winer EP. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. JNCI. 2026 Apr 1;118(4):669-679. doi: 10.1093/jnci/djaf344. PMID: 41418409. \n View Paper\n
Analysis of oral and invited faculty representation of international medical graduates at the ASCO Annual Meetings.
\n\n \n \n\n \n
Recommended citation: Roy AM, Bakouny Z, Dizman N, Paul MA, Ozay ZI, Lal BM, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Xie W, Lee AJ, Choueiri TK. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings. JCO Oncol Pract. 2026 Apr;22(4):708-716. doi: 10.1200/OP-25-00067. Epub 2025 Jun 27. PMID: 40577682. \n View Paper\n
Published in Nature Reviews Clinical Oncology, 2026
\n\n \n\n \n
\n
State-of-the-art review of HIF2α inhibition, highlighting the biological discoveries, structural breakthroughs, and clinical advances that established HIF2α inhibitors as a therapeutic strategy in kidney cancer and other hypoxia-driven malignancies.
\n\n \n \n\n \n
Recommended citation: Saad E†, Machaalani M†, McDermott DF, Choueiri TK. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology. 2026. doi: 10.1038/s41571-026-01145-y. †Equal contribution. \n View Paper\n
Multi-cohort study integrating plasma metabolomics, metagenomics, and clinical data to identify metabolic determinants of immunotherapy outcomes, linking histidine with improved survival and long-chain fatty acids and succinate with worse outcomes across advanced cancer types.
\n\n \n \n\n \n
Recommended citation: Suissa D, Fidelle M, Reich E, Pham TN, Thomas S, Björk JR, Liu P, Zhao L, Kitaoka K, Piard E, Lebhar I, Tian AL, Thelemaque C, Alves Costa Silva C, Deutsch E, Loriot Y, Segata N, Piccinno G, Hospers GAP, Maleki Vareki S, Silverman MS, Lenehan JG, Bataille V, Boulate D, Kuznetsova T, Weersma RK, Messaoudene M, Durand S, van der Aalst CM, de Koning HJ, Schuler-Thurner B, de Vries IJM, Rafie E, Saliby RM, Machaalani M, Haferkamp S, Schilling B, Porcari S, Ciccarese C, Iacovelli R, Cremolini C, Choueiri TK, Elkrief A, Kroemer G, Heinzerling L, Chamoto K, Ianiro G, Routy B, Derosa L, Paragios N, Zitvogel L. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. Nature Medicine. 2026. doi: 10.1038/s41591-026-04481-9. \n View Paper\n
Multi-modal analysis of DNA and RNA sequencing data from patients with renal cell carcinoma treated with first-line immunotherapy, identifying molecular and immune correlates of LAG-3 expression and an association between higher LAG-3 expression and improved early real-world response.
\n\n \n \n\n \n
Recommended citation: Dudipala H, Dugan AJ, Jariwala U, Ronski K, Mercer J, Saad E, El Masri J, Machaalani M, Saleh M, Viets Layng K, Yu Y, Signoretti S, Braun D, Pal SK, Choueiri TK, McKay RR. Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma. The Oncologist. 2026;31(9):oyag317. doi: 10.1093/oncolo/oyag317. \n View Paper\n
Published in The Journal of Clinical Investigation, 2026
\n\n \n\n \n
\n
In primary human T cells and patient samples, pharmacologic HIF-2α inhibition with belzutifan preserved proliferation, cytokine production, cytotoxicity, and activation states, supporting its immunologic safety in clear cell renal cell carcinoma.
\n\n \n \n\n \n
Recommended citation: Madsen KN, Kashima S, Soulati H, Wirth L, Ito K, Yochum ZA, Moritz V, Walker J, Machaalani M, Ghali F, Kenney P, Adeniran A, Hurwitz M, Choueiri TK, Braun DA. Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma. J Clin Invest. 2026 Oct 6:e204613. doi: 10.1172/JCI204613. \n View Paper\n
Published in Journal of the National Cancer Institute, 2026
\n\n \n\n \n
\n
A nationwide real-world study in metastatic breast cancer evaluates intermediate clinical endpoints against overall survival and proposes a framework for validating endpoints in oncology data.
\n\n \n \n\n \n
Recommended citation: Labaki C, Bakouny Z, Sanglier T, Saad E, Valero Martin M, Tarantino P, Schmidt AL, Shim J, Braun DA, Bouquet F, Joyce M, Machaalani M, Van Allen EM, Xie W, Tolaney SM, Choueiri TK. Novel framework for the validation of intermediate clinical endpoints in oncology real-world data. J Natl Cancer Inst. 2026 Oct 19:djag390. doi: 10.1093/jnci/djag390. \n View Paper\n
Discussing the knowledge, precautionary behaviors, and psychological impact of the first COVID-19 wave on patients with cardiovascular disease in Lebanon.
Invited talk at the Society for Immunotherapy of Cancer (SITC) Leveraging Biomarkers to Accelerate IO Drug Development Workshop, focused on practical implementation of immunotherapy biomarkers in genitourinary cancers.
Evaluating soluble mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) as a prognostic biomarker in metastatic renal cell carcinoma across three independent clinical trials.
Evaluating whether real-world endpoints can serve as surrogate markers for overall survival in metastatic bladder cancer using a large real-world cohort.
Evaluating whether integrating KIM-1 and MAdCAM-1 into a composite risk score improves risk stratification beyond either biomarker alone and beyond IMDC criteria in metastatic renal carcinoma.
This is a description of a teaching experience. You can use markdown like any other post.
\n\n\n \n \n\n \n\n \n
\n \n \n","media":{"gallery":[]}},{"path":"_pages/contact.html","url":"/contact/","title":"Contact","fields":{ "title":"Contact","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"For research collaborations, academic questions, and other inquiries."},"body":"
\n
Send a note using the form below. Please do not include patient information or other sensitive personal information.
\nThere is quite a bit more to life than medicine. \n\nI studied piano at the Lebanese National Higher Conservatory of Music from 2006 to 2021, earning a Bachelor's Degree with High Distinction. You can find some of my music on my [YouTube channel](https://www.youtube.com/@MarcMachaalani).\n\n
\n \n
\n\n\nWhen I have an afternoon free, I like to play tennis, go for a bike ride, or spend a little time with friends in nature around New Haven. I also enjoy a game of chess. You can find me on [Lichess](https://lichess.org/@/Marcotitto).\n\nMy bookshelves lean toward classics and history. I keep track of what I’m reading on [Goodreads](https://www.goodreads.com/marcmachaalani). I also keep a film diary on [Letterboxd](https://letterboxd.com/Marcotitto/).\n\n\n","media":{"gallery":[]}},{"path":"_pages/markdown.md","url":"/markdown/","title":"Markdown","fields":{ "title":"Markdown","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include toc %}\n\n## Locations of key files/directories\n\n* Basic config options: _config.yml\n* Top navigation bar config: _data/navigation.yml\n* Single pages: _pages/\n* Collections of pages are .md or .html files in:\n * _publications/\n * _portfolio/\n * _posts/\n * _teaching/\n * _talks/\n* Footer: _includes/footer.html\n* Static files (like PDFs): /files/\n* Profile image (can set in _config.yml): images/profile.png\n\n## Tips and hints\n\n* Name a file \".md\" to have it render in markdown, name it \".html\" to render in HTML.\n* Go to the [commit list](https://github.com/academicpages/academicpages.github.io/commits/master) (on your repo) to find the last version GitHub built with Jekyll. \n * Green check: successful build\n * Orange circle: building\n * Red X: error\n * No icon: not built\n\n* Academic Pages uses [Jekyll Kramdown](https://jekyllrb.com/docs/configuration/markdown/), GitHub Flavored Markdown (GFM) parser, which is similar to the version of Markdown used on GitHub, but may have some minor differences. \n * Some of emoji supported on GitHub should be supposed via the [Jemoji](https://github.com/jekyll/jemoji) plugin :computer:.\n * The best list of the supported emoji can be found in the [Emojis for Jekyll via Jemoji](https://www.fabriziomusacchio.com/blog/2021-08-16-emojis_for_Jekyll/#computer) blog post.\n\n* While GitHub Pages prevents server side code from running, client-side scripts are supported.\n * This means that Google Analytics is supported, and [the wiki](https://github.com/academicpages/academicpages.github.io/wiki/Adding-Google-Analytics) should contain the most up-to-date information on getting it working.\n\n* Your CV can be written using either Markdown ([preview](https://academicpages.github.io/cv/)) or generated via JSON ([preview](https://academicpages.github.io/cv-json/)) and the layouts are slightly different. You can update the path to the one being used in `_data/navigation.yml` with the JSON formatted CV being hidden by default.\n\n * The [Liquid syntax guide](https://shopify.github.io/liquid/tags/control-flow/) is a useful guide for those that want to add functionality to the template or to become contributors to the [template on GitHub](https://github.com/academicpages/academicpages.github.io).\n\n## MathJax \n\nSupport for MathJax (version 3.* via [jsDelivr](https://www.jsdelivr.com/), [documentation](https://docs.mathjax.org/en/latest/)) is included in the template:\n\n$$\n\\displaylines{\n\\nabla \\cdot E= \\frac{\\rho}{\\epsilon_0} \\\\\\\n\\nabla \\cdot B=0 \\\\\\\n\\nabla \\times E= -\\partial_tB \\\\\\\n\\nabla \\times B = \\mu_0 \\left(J + \\varepsilon_0 \\partial_t E \\right)\n}\n$$\n\nThe default delimiters of `$$...$$` and `\\\\[...\\\\]` are supported for displayed mathematics, while `\\\\(...\\\\)` should be used for in-line mathematics (ex., \\\\(a^2 + b^2 = c^2\\\\))\n\n**Note** that since Academic Pages uses Markdown which cases some interference with MathJax and LaTeX for escaping characters and new lines, although [some workarounds exist](https://math.codidact.com/posts/278763/278772#answer-278772). In some cases, such as when you are including MathJax in a `citation` field for publications, it may be necessary to use `\\(...\\)` for inline delineation.\n\n## Mermaid diagrams\nAcademic Pages includes support for [Mermaid diagrams](https://mermaid.js.org/) (version 11.* via [jsDelivr](https://www.jsdelivr.com/)) and in addition to their [tutorials](https://mermaid.js.org/ecosystem/tutorials.html) and [GitHub documentation](https://github.com/mermaid-js/mermaid) the basic syntax is as follows:\n\n```markdown\n ```mermaid\n graph LR\n A-->B\n ```\n```\n\nWhich produces the following plot with the [default theme](https://mermaid.js.org/config/theming.html) applied:\n\n```mermaid\ngraph LR\nA-->B\n```\n\nWhile a more advanced plot with the `forest` theme applied looks like the following:\n\n```mermaid\n---\nconfig:\n theme: 'forest'\n---\ngraph TD;\n A-->B;\n A-->C;\n B-->D;\n C-->D;\n```\n\n## Plotly\nAcademic Pages includes support for Plotly diagrams via a hook in the Markdown code elements, although those that are comfortable with HTML and JavaScript can also access it [via those routes](https://plotly.com/javascript/getting-started/). Plotly is included via an `npm` [package](https://www.npmjs.com/package/plotly.js?activeTab=readme) and is distributed as part of the minimized JavaScript that is part of the template.\n\nIn order to render a Plotly plot via Markdown the relevant plot data need to be added as follows:\n\n```markdown\n ```plotly\n {\n \"data\": [\n {\n \"x\": [1, 2, 3, 4],\n \"y\": [10, 15, 13, 17],\n \"type\": \"scatter\"\n },\n {\n \"x\": [1, 2, 3, 4],\n \"y\": [16, 5, 11, 9],\n \"type\": \"scatter\"\n }\n ]\n }\n ```\n```\n\n**Important!** Since the data is parsed as JSON *all* of the keys will need to be quoted for the plot to render. The use of a tool like [JSONLint](https://jsonlint.com/) to check syntax is highly recommended.\n{: .notice}\n\nWhich produces the following:\n```plotly\n{\n \"data\": [\n {\n \"x\": [1, 2, 3, 4],\n \"y\": [10, 15, 13, 17],\n \"type\": \"scatter\"\n },\n {\n \"x\": [1, 2, 3, 4],\n \"y\": [16, 5, 11, 9],\n \"type\": \"scatter\"\n }\n ]\n}\n```\n\nEssentially what is taking place is that the [Plotly attributes](https://plotly.com/javascript/reference/index/) are being taken from the code block as JSON data, parsed, and passed to Plotly along with a theme that matches the current site theme (i.e., a light theme, or a dark theme). This allows all plots that can be described via the `data` attribute to rendered with some limitations for the theme of the plot.\n\n```plotly\n{\n \"data\": [\n {\n \"x\": [1, 2, 3, 4, 5],\n \"y\": [1, 6, 3, 6, 1],\n \"mode\": \"markers\",\n \"type\": \"scatter\",\n \"name\": \"Team A\",\n \"text\": [\"A-1\", \"A-2\", \"A-3\", \"A-4\", \"A-5\"],\n \"marker\": { \"size\": 12 }\n },\n {\n \"x\": [1.5, 2.5, 3.5, 4.5, 5.5],\n \"y\": [4, 1, 7, 1, 4],\n \"mode\": \"markers\",\n \"type\": \"scatter\",\n \"name\": \"Team B\",\n \"text\": [\"B-a\", \"B-b\", \"B-c\", \"B-d\", \"B-e\"],\n \"marker\": { \"size\": 12 }\n } \n ],\n \"layout\": {\n \"xaxis\": {\n \"range\": [ 0.75, 5.25 ]\n },\n \"yaxis\": {\n \"range\": [0, 8]\n },\n \"title\": {\"text\": \"Data Labels Hover\"}\n }\n}\n```\n\n```plotly\n{\n \"data\": [{\n \"x\": [1, 2, 3],\n \"y\": [4, 5, 6],\n \"type\": \"scatter\"\n },\n {\n \"x\": [20, 30, 40],\n \"y\": [50, 60, 70],\n \"xaxis\": \"x2\",\n \"yaxis\": \"y2\",\n \"type\": \"scatter\"\n }],\n \"layout\": {\n \"grid\": {\n \"rows\": 1,\n \"columns\": 2,\n \"pattern\": \"independent\"\n },\n \"title\": {\n \"text\": \"Simple Subplot\"\n } \n }\n}\n```\n\n```plotly\n{\n \"data\": [{\n\t\t\"z\": [[10, 10.625, 12.5, 15.625, 20],\n [5.625, 6.25, 8.125, 11.25, 15.625],\n [2.5, 3.125, 5.0, 8.125, 12.5],\n [0.625, 1.25, 3.125, 6.25, 10.625],\n [0, 0.625, 2.5, 5.625, 10]],\n\t\t\"type\": \"contour\"\n\t}],\n \"layout\": {\n \"title\": {\n \"text\": \"Basic Contour Plot\"\n }\n }\n}\n```\n\n## Markdown guide\n\nAcademic Pages uses [kramdown](https://kramdown.gettalong.org/index.html) for Markdown rendering, which has some differences from other Markdown implementations such as GitHub's. In addition to this guide, please see the [kramdown Syntax page](https://kramdown.gettalong.org/syntax.html) for full documentation. \n\n### Header three\n\n#### Header four\n\n##### Header five\n\n###### Header six\n\n## Blockquotes\n\nSingle line blockquote:\n\n> Quotes are cool.\n\n## Tables\n\n### Table 1\n\n| Entry | Item | |\n| -------- | ------ | ------------------------------------------------------------ |\n| [John Doe](#) | 2016 | Description of the item in the list |\n| [Jane Doe](#) | 2019 | Description of the item in the list |\n| [Doe Doe](#) | 2022 | Description of the item in the list |\n\n### Table 2\n\n| Header1 | Header2 | Header3 |\n|:--------|:-------:|--------:|\n| cell1 | cell2 | cell3 |\n| cell4 | ce\nll5 | cell6 |\n|-----------------------------|\n| cell1 | cell2 | cell3 |\n| cell4 | cell5 | cell6 |\n|=============================|\n| Foot1 | Foot2 | Foot3 |\n\n## Definition Lists\n\nDefinition List Title\n: Definition list division.\n\nStartup\n: A startup company or startup is a company or temporary organization designed to search for a repeatable and scalable business model.\n\n#dowork\n: Coined by Rob Dyrdek and his personal body guard Christopher \"Big Black\" Boykins, \"Do Work\" works as a self motivator, to motivating your friends.\n\nDo It Live\n: I'll let Bill O'Reilly [explain](https://www.youtube.com/watch?v=O_HyZ5aW76c \"We'll Do It Live\") this one.\n\n## Unordered Lists (Nested)\n\n * List item one \n * List item one \n * List item one\n * List item two\n * List item three\n * List item four\n * List item two\n * List item three\n * List item four\n * List item two\n * List item three\n * List item four\n\n## Ordered List (Nested)\n\n 1. List item one \n 1. List item one \n 1. List item one\n 2. List item two\n 3. List item three\n 4. List item four\n 2. List item two\n 3. List item three\n 4. List item four\n 2. List item two\n 3. List item three\n 4. List item four\n\n## Buttons\n\nMake any link standout more when applying the `.btn` class.\n\n## Notices\n\nBasic notices or call-outs are supported using the following syntax:\n\n```markdown\n**Watch out!** You can also add notices by appending `{: .notice}` to the line following paragraph.\n{: .notice}\n```\n\nwhich wil render as:\n\n**Watch out!** You can also add notices by appending `{: .notice}` to the line following paragraph.\n{: .notice}\n\n### Footnotes\n\nFootnotes can be useful for clarifying points in the text, or citing information.[^1] Markdown support numeric footnotes, as well as text as long as the values are unique.[^note]\n\n```markdown\nThis is the regular text.[^1] This is more regular text.[^note]\n\n[^1]: This is the footnote itself.\n[^note]: This is another footnote.\n```\n\n[^1]: Such as this footnote.\n[^note]: When using text for footnotes markers, no spaces are permitted in the name.\n\n## HTML Tags\n\n### Address Tag\n\n\n 1 Infinite Loop Cupertino, CA 95014 United States\n\n\n### Anchor Tag (aka. Link)\n\nThis is an example of a [link](https://github.com \"GitHub\").\n\n### Abbreviation Tag\n\nThe abbreviation CSS stands for \"Cascading Style Sheets\".\n\n*[CSS]: Cascading Style Sheets\n\n### Cite Tag\n\n\"Code is poetry.\" ---Automattic\n\n### Code Tag\n\nYou will learn later on in these tests that `word-wrap: break-word;` will be your best friend.\n\nYou can also write larger blocks of code with syntax highlighting supported for some languages, such as Python:\n\n```python\nprint('Hello World!')\n```\n\nor R:\n\n```R\nprint(\"Hello World!\", quote = FALSE)\n```\n\n### Details Tag (collapsible sections)\n\nThe HTML `` tag works well with Markdown and allows you to include collapsible sections, see [W3Schools](https://www.w3schools.com/tags/tag_details.asp) for more information on how to use the tag.\n\n\n Collapsed by default\n This section was collapsed by default!\n\n\nThe source code:\n\n```HTML\n\n Collapsed by default\n This section was collapsed by default!\n\n```\n\nOr, you can leave a section open by default by including the `open` attribute in the tag:\n\n\n Open by default\n This section is open by default thanks to open in the <details open> tag!\n\n\n\n### Emphasize Tag\n\nThe emphasize tag should _italicize_ text.\n\n### Insert Tag\n\nThis tag should denote inserted text.\n\n### Keyboard Tag\n\nThis scarcely known tag emulates keyboard text, which is usually styled like the `` tag.\n\n### Preformatted Tag\n\nThis tag styles large blocks of code.\n\n
\n.post-title {\n margin: 0 0 5px;\n font-weight: bold;\n font-size: 38px;\n line-height: 1.2;\n and here's a line of some really, really, really, really long text, just to see how the PRE tag handles it and to find out how it overflows;\n}\n
\n\n### Quote Tag\n\nDevelopers, developers, developers… –Steve Ballmer\n\n### Strike Tag\n\nThis tag will let you strikeout text.\n\n### Strong Tag\n\nThis tag shows **bold text**.\n\n### Subscript Tag\n\nGetting our science styling on with H2O, which should push the \"2\" down.\n\n### Superscript Tag\n\nStill sticking with science and Isaac Newton's E = MC2, which should lift the 2 up.\n\n### Variable Tag\n\nThis allows you to denote variables.\n\n***\n**Footnotes**\n\nThe footnotes in the page will be returned following this line, return to the section on Markdown Footnotes.\n\n","media":{"gallery":[]}},{"path":"_pages/media.html","url":"/media/","title":"Media","fields":{ "title":"Media","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"Interviews and other coverage."},"body":"{% include base_path %}\n\n{% assign videos = site.media | where: \"category\", \"video\" %}\n{% assign articles = site.media | where: \"category\", \"article\" %}\n\n{% if videos.size > 0 %}\n \n
\n
Video interviews
\n
\n
\n {% for post in videos reversed %}\n {% include archive-single-media.html %}\n {% endfor %}\n
\n \n{% endif %}\n\n{% if articles.size > 0 %}\n \n
\n
Articles
\n
\n
\n {% for post in articles reversed %}\n {% include archive-single-media.html %}\n {% endfor %}\n
\n \n{% endif %}\n","media":{"gallery":[]}},{"path":"_pages/non-menu-page.md","url":"/non-menu-page/","title":"Page not in menu","fields":{ "title":"Page not in menu","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"This is a page not in the menu. You can use markdown in this page.\n\nHeading 1\n======\n\nHeading 2\n======\n","media":{"gallery":[]}},{"path":"_pages/page-archive.html","url":"/page-archive/","title":"Page Archive","fields":{ "title":"Page Archive","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include base_path %}\n{% for post in site.pages %}\n {% include archive-single.html %}\n{% endfor %}","media":{"gallery":[]}},{"path":"_pages/portfolio.html","url":"/portfolio/","title":"Portfolio","fields":{ "title":"Portfolio","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include base_path %}\n\n\n{% for post in site.portfolio %}\n {% include archive-single.html %}\n{% endfor %}\n\n","media":{"gallery":[]}},{"path":"_pages/privacy.md","url":"/privacy/","title":"Privacy","fields":{ "title":"Privacy","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"A small site, with minimal data collection."},"body":"{% if site.data.services.analytics_enabled %}\nThis site counts page views to understand which pages are useful. It stores only a page path, a UTC calendar date, and an aggregate count, retained for up to 90 days. It does not use analytics cookies, visitor IDs, fingerprinting, or cross-site tracking. Search terms, URL query strings, referring pages, and IP addresses are not stored in the analytics database. Counts measure page views, not unique people, and may include automated traffic. The script respects Do Not Track and Global Privacy Control.\n{% else %}\nSite usage analytics are currently disabled.\n{% endif %}\n\nWhen enabled, the contact form sends your name, email address, subject, and message to me by email through Cloudflare and Resend. These services process the message to deliver it and prevent abuse. Messages are not saved in this website's database or repository. Cloudflare Turnstile checks submissions for spam. Network addresses are processed transiently for delivery and rate limiting.\n\nGitHub Pages hosts the public site. GitHub, Cloudflare, and the email provider may process connection information and retain operational logs under their own policies. The application's analytics database contains no connection logs.\n\nThe private editor uses a short-lived, secure sign-in cookie and GitHub authentication. Drafts are stored privately in Cloudflare D1. Only the version the owner publishes is returned to visitors. Content edits do not create GitHub commits or pull requests. GitHub Pages continues to host the site’s layout and a baseline copy of the content.\n\nEmbedded videos and links to other websites have their own privacy practices. You may contact me about information you have sent through the [contact page](/contact/).\n\nThe owner editor stores uploaded PDFs and photos privately. Paper PDFs have no public download route. Photos become public only when added to a published page. Uploads used only in an unpublished draft stay private.\n","media":{"gallery":[]}},{"path":"_pages/publications.html","url":"/publications/","title":"Publications","fields":{ "title":"Publications","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"Journal articles and other selected publications."},"body":"{% if site.author.googlescholar %}\n \n View on Google Scholar\n \n{% endif %}\n\n{% include base_path %}\n\n\n\n
No publications match these filters. Try a broader search or clear the filters.
\n\n\n\n\n{% if site.publication_category %}\n
\n {% for category in site.publication_category %}\n {% assign title_shown = false %}\n {% assign category_items = 0 %}\n \n \n {% for post in site.publications %}\n {% if post.category == category[0] %}\n {% assign category_items = category_items | plus: 1 %}\n {% endif %}\n {% endfor %}\n \n {% if category_items > 0 %}\n \n
\n
{{ category[1].title }}
\n
\n \n \n
\n {% for post in site.publications reversed %}\n {% if post.category == category[0] %}\n {% include archive-single-publication.html %}\n {% endif %}\n {% endfor %}\n
\n \n {% endif %}\n {% endfor %}\n
\n{% else %}\n
\n
\n {% for post in site.publications reversed %}\n {% include archive-single-publication.html %}\n {% endfor %}\n
\n
\n{% endif %}\n","media":{"gallery":[]}},{"path":"_pages/tag-archive.html","url":"/tags/","title":"Posts by Tags","fields":{ "title":"Posts by Tags","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include base_path %}\n{% include group-by-array collection=site.posts field=\"tags\" %}\n\n{% for tag in group_names %}\n {% assign posts = group_items[forloop.index0] %}\n
{{ tag }}
\n {% for post in posts %}\n {% include archive-single.html %}\n {% endfor %}\n{% endfor %}","media":{"gallery":[]}},{"path":"_pages/talkmap.html","url":"/talkmap.html","title":"Talk map","fields":{ "title":"Talk map","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
This map is generated from a Jupyter Notebook file in talkmap.ipynb, which mines the location fields in the .md files in _talks/.
\n\n","media":{"gallery":[]}},{"path":"_pages/talks.html","url":"/talks/","title":"Presentations","fields":{ "title":"Presentations","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":"Oral presentations, posters, and invited talks."},"body":"{% include base_path %}\n\n{% if site.talkmap_link == true %}\n
","media":{"gallery":[]}},{"path":"_pages/teaching.html","url":"/teaching/","title":"Teaching","fields":{ "title":"Teaching","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include base_path %}\n\n{% for post in site.teaching reversed %}\n {% include archive-single.html %}\n{% endfor %}\n","media":{"gallery":[]}},{"path":"_pages/terms.md","url":"/terms/","title":"Terms and Privacy Policy","fields":{ "title":"Terms and Privacy Policy","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"","media":{"gallery":[]}},{"path":"_pages/year-archive.html","url":"/year-archive/","title":"Blog posts","fields":{ "title":"Blog posts","date":"","excerpt":"","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"{% include base_path %}\n{% capture written_year %}'None'{% endcapture %}\n{% for post in site.posts %}\n {% capture year %}{{ post.date | date: '%Y' }}{% endcapture %}\n {% if year != written_year %}\n
{{ year }}
\n {% capture written_year %}{{ year }}{% endcapture %}\n {% endif %}\n {% include archive-single.html %}\n{% endfor %}\n","media":{"gallery":[]}},{"path":"_media/2024-02-01-onkologi-immune-signatures.md","url":"/media/2024-02-01-onkologi-immune-signatures/","title":"Immune signatures as predictors for immunotherapy regimens in metastatic RCC","fields":{ "title":"Immune signatures as predictors for immunotherapy regimens in metastatic RCC","date":"2024-02-01","excerpt":"
Discussion on host immune signatures as predictive biomarkers for immunotherapy response in metastatic RCC.
Discussion on host immune signatures as predictive biomarkers for immunotherapy response in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_media/2024-05-15-asco-daily-ici-rechallenge.md","url":"/media/2024-05-15-asco-daily-ici-rechallenge/","title":"Examining the evidence on immunotherapy rechallenge after prior ICI exposure in mRCC","fields":{ "title":"Examining the evidence on immunotherapy rechallenge after prior ICI exposure in mRCC","date":"2024-05-15","excerpt":"
ASCO Daily News feature analyzing the evidence for immunotherapy rechallenge in metastatic RCC.
ASCO Daily News feature analyzing the evidence for immunotherapy rechallenge in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_media/2024-05-25-oncodaily-ici-rechallenge.md","url":"/media/2024-05-25-oncodaily-ici-rechallenge/","title":"Immunotherapy rechallenge after prior immune checkpoint inhibition in mRCC","fields":{ "title":"Immunotherapy rechallenge after prior immune checkpoint inhibition in mRCC","date":"2024-05-25","excerpt":"
Commentary on immunotherapy rechallenge strategies after prior immune checkpoint inhibition in metastatic RCC.
Commentary on immunotherapy rechallenge strategies after prior immune checkpoint inhibition in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_media/2024-07-19-onclive-axl-cmet.md","url":"/media/2024-07-19-onclive-axl-cmet/","title":"Dr Machaalani on overcoming acquired resistance through AXL and c-MET inhibition in RCC","fields":{ "title":"Dr Machaalani on overcoming acquired resistance through AXL and c-MET inhibition in RCC","date":"2024-07-19","excerpt":"
Discussion on targeting AXL and c-MET pathways to overcome acquired resistance in renal cell carcinoma.
Discussion on targeting AXL and c-MET pathways to overcome acquired resistance in renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2024-09-14-ecancer-erbb2.md","url":"/media/2024-09-14-ecancer-erbb2/","title":"ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies","fields":{ "title":"ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies","date":"2024-09-14","excerpt":"
Video feature on ERBB2 amplification patterns and implications for HER2-targeted therapies.
Video feature on ERBB2 amplification patterns and implications for HER2-targeted therapies.
\n","media":{"gallery":[]}},{"path":"_media/2024-10-04-onclive-erbb2-amplification.md","url":"/media/2024-10-04-onclive-erbb2-amplification/","title":"Dr Machaalani on the incidence of ERBB2 amplifications across race, sex, and cancer type","fields":{ "title":"Dr Machaalani on the incidence of ERBB2 amplifications across race, sex, and cancer type","date":"2024-10-04","excerpt":"
Discussion on ERBB2 amplification patterns across demographic and cancer subtypes.
Discussion on ERBB2 amplification patterns across demographic and cancer subtypes.
\n","media":{"gallery":[]}},{"path":"_media/2025-05-30-guoncology-elevated-kim1.md","url":"/media/2025-05-30-guoncology-elevated-kim1/","title":"Elevated KIM-1 levels are associated with poor prognosis in metastatic RCC","fields":{ "title":"Elevated KIM-1 levels are associated with poor prognosis in metastatic RCC","date":"2025-05-30","excerpt":"
Report highlighting the prognostic implications of elevated circulating KIM-1 levels in metastatic renal cell carcinoma.
Report highlighting the prognostic implications of elevated circulating KIM-1 levels in metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2025-06-11-guoncology-kim1-biology.md","url":"/media/2025-06-11-guoncology-kim1-biology/","title":"Characterization of circulating KIM-1: correlation with protein levels and tumor biology in metastatic RCC","fields":{ "title":"Characterization of circulating KIM-1: correlation with protein levels and tumor biology in metastatic RCC","date":"2025-06-11","excerpt":"
Analysis of the biological and clinical correlates of circulating KIM-1 in metastatic renal cell carcinoma.
Analysis of the biological and clinical correlates of circulating KIM-1 in metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2025-07-02-onclive-low-kim1.md","url":"/media/2025-07-02-onclive-low-kim1/","title":"Low KIM-1 levels are associated with improved clinical outcomes in advanced RCC","fields":{ "title":"Low KIM-1 levels are associated with improved clinical outcomes in advanced RCC","date":"2025-07-02","excerpt":"
Coverage on the clinical implications of low circulating KIM-1 levels in advanced renal cell carcinoma.
Coverage on the clinical implications of low circulating KIM-1 levels in advanced renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2025-07-17-onclive-kim1-role.md","url":"/media/2025-07-17-onclive-kim1-role/","title":"Dr Machaalani on the potential role of circulating KIM-1 as a biomarker in metastatic RCC","fields":{ "title":"Dr Machaalani on the potential role of circulating KIM-1 as a biomarker in metastatic RCC","date":"2025-07-17","excerpt":"
Discussion on the emerging role of circulating KIM-1 as a biomarker in metastatic renal cell carcinoma.
Discussion on the emerging role of circulating KIM-1 as a biomarker in metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2025-10-18-vj-oncology-madcam1.md","url":"/media/2025-10-18-vj-oncology-madcam1/","title":"Soluble MAdCAM-1 as a prognostic biomarker in metastatic RCC","fields":{ "title":"Soluble MAdCAM-1 as a prognostic biomarker in metastatic RCC","date":"2025-10-18","excerpt":"
Featured interview at ESMO 2025 discussing the role of soluble MAdCAM-1 as a prognostic biomarker in metastatic renal cell carcinoma.
\n","venue":"The Video Journal of Oncology (VJOncology)","article_type":"","topics":"","paperurl":"https://www.vjoncology.com/video/1pulncji2jw-soluble-madcam-1-as-a-prognostic-biomarker-in-metastatic-rcc/","pubmed":"","citation":"","intro":""},"body":"
Featured interview at ESMO 2025 discussing the role of soluble MAdCAM-1 as a prognostic biomarker in metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_media/2025-11-11-urology-times-madcam1.md","url":"/media/2025-11-11-urology-times-madcam1/","title":"Marc Machaalani, MD, on soluble MAdCAM-1 in metastatic renal cell carcinoma","fields":{ "title":"Marc Machaalani, MD, on soluble MAdCAM-1 in metastatic renal cell carcinoma","date":"2025-11-11","excerpt":"
Commentary on the clinical relevance of soluble MAdCAM-1 in metastatic renal cell carcinoma.
Commentary on the clinical relevance of soluble MAdCAM-1 in metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_portfolio/portfolio-1.md","url":"/portfolio/portfolio-1/","title":"Portfolio item number 1","fields":{ "title":"Portfolio item number 1","date":"","excerpt":"Short description of portfolio item number 1 ","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
This is an item in your portfolio. It can be have images or nice text. If you name the file .md, it will be parsed as markdown. If you name the file .html, it will be parsed as HTML.
\n","media":{"gallery":[]}},{"path":"_portfolio/portfolio-2.html","url":"/portfolio/portfolio-2/","title":"Portfolio item number 2","fields":{ "title":"Portfolio item number 2","date":"","excerpt":"Short description of portfolio item number 2 ","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"This is an item in your portfolio. It can be have images or nice text. If you name the file .md, it will be parsed as markdown. If you name the file .html, it will be parsed as HTML. \n","media":{"gallery":[]}},{"path":"_posts/2012-01-01-future-post.md","url":"/posts/2012/08/blog-post-4/","title":"Future Blog Post","fields":{ "title":"Future Blog Post","date":"2012-01-01","excerpt":"
This post will show up by default. To disable scheduling of future posts, edit config.yml and set future: false.
This post will show up by default. To disable scheduling of future posts, edit config.yml and set future: false.
\n","media":{"gallery":[]}},{"path":"_posts/2012-08-14-blog-post-1.md","url":"/posts/2012/08/blog-post-1/","title":"Blog Post number 1","fields":{ "title":"Blog Post number 1","date":"2012-08-14","excerpt":"
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
\n\n
Headings are cool
\n\n
You can have many headings
\n\n
Aren’t headings cool?
\n","media":{"gallery":[]}},{"path":"_posts/2013-08-14-blog-post-2.md","url":"/posts/2013/08/blog-post-2/","title":"Blog Post number 2","fields":{ "title":"Blog Post number 2","date":"2013-08-14","excerpt":"
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
\n\n
Headings are cool
\n\n
You can have many headings
\n\n
Aren’t headings cool?
\n","media":{"gallery":[]}},{"path":"_posts/2014-08-14-blog-post-3.md","url":"/posts/2014/08/blog-post-3/","title":"Blog Post number 3","fields":{ "title":"Blog Post number 3","date":"2014-08-14","excerpt":"
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.
\n\n
Headings are cool
\n\n
You can have many headings
\n\n
Aren’t headings cool?
\n","media":{"gallery":[]}},{"path":"_publications/2021-10-01-arab-transplant-bibliometric.md","url":"/publications/2021-10-01-arab-transplant-bibliometric/","title":"Contribution of Arab World in Transplant Research: A PubMed-Based Bibliometric Analysis","fields":{ "title":"Contribution of Arab World in Transplant Research: A PubMed-Based Bibliometric Analysis","date":"2021-10-01","excerpt":"Bibliometric analysis evaluating the volume, trends, and global contribution of transplant-related research output from the Arab world between 2005 and 2019.","venue":"Transplant Immunology","article_type":"Journal Article","topics":"Public health","paperurl":"https://doi.org/10.1016/j.trim.2021.101432","pubmed":"https://pubmed.ncbi.nlm.nih.gov/34186171/","citation":"El Ayoubi LM, El Masri J, Machaalani M, El Hage S, Salameh P. Contribution of Arab World in Transplant Research: A PubMed-Based Bibliometric Analysis. Transpl Immunol. 2021;68:101432. doi:10.1016/j.trim.2021.101432.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2022-04-23-drug-repurposing-colon-cancer.md","url":"/publications/2022-04-23-drug-repurposing-colon-cancer/","title":"Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing","fields":{ "title":"Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing","date":"2022-04-23","excerpt":"Comprehensive review of repurposed pharmacologic agents as strategies to overcome therapeutic resistance in colorectal cancer.","venue":"Cancers","article_type":"Review","topics":"Targeted therapies","paperurl":"https://doi.org/10.3390/cancers14092105","pubmed":"https://pubmed.ncbi.nlm.nih.gov/35565237/","citation":"El Zarif T, Yibrin M, De Oliveira-Gomes D, Machaalani M, Nawfal R, Bittar G, Bahmad HF, Bitar N. Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing. Cancers (Basel). 2022;14(9):2105. doi:10.3390/cancers14092105.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2022-07-13-hypertension-kap-lebanon.md","url":"/publications/2022-07-13-hypertension-kap-lebanon/","title":"Knowledge, Attitude, and Practice Toward Hypertension Among Hypertensive Patients Residing in Lebanon","fields":{ "title":"Knowledge, Attitude, and Practice Toward Hypertension Among Hypertensive Patients Residing in Lebanon","date":"2022-07-13","excerpt":"Cross-sectional study evaluating hypertension knowledge, attitudes, and clinical practices among hypertensive patients in Lebanon.","venue":"Vascular Health and Risk Management","article_type":"Journal Article","topics":"Public health","paperurl":"https://doi.org/10.2147/VHRM.S367187","pubmed":"https://pubmed.ncbi.nlm.nih.gov/35860751/","citation":"Machaalani M, Seifeddine H, Ali A, Bitar H, Briman O, Chahine MN. Knowledge, Attitude, and Practice Toward Hypertension Among Hypertensive Patients Residing in Lebanon. Vasc Health Risk Manag. 2022;18:541-553. doi:10.2147/VHRM.S367187.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2022-07-29-cvd-kap-lebanon.md","url":"/publications/2022-07-29-cvd-kap-lebanon/","title":"Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population","fields":{ "title":"Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population","date":"2022-07-29","excerpt":"Case-control study assessing cardiovascular disease knowledge, attitudes, and preventive practices among Lebanese adults.","venue":"Global Heart","article_type":"Journal Article","topics":"Public health","paperurl":"https://doi.org/10.5334/gh.1138","pubmed":"https://pubmed.ncbi.nlm.nih.gov/36051313/","citation":"Machaalani M, Fakhry B, Zwaideh M, Mendelek K, Mahmoud N, Hammoud T, Chahine MN. Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population. Global Heart. 2022;17(1):47. doi:10.5334/gh.1138.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2022-11-17-arab-cancer-research-bibliometric.md","url":"/publications/2022-11-17-arab-cancer-research-bibliometric/","title":"Cancer research activity in the Arab world: a 15-year bibliometric analysis","fields":{ "title":"Cancer research activity in the Arab world: a 15-year bibliometric analysis","date":"2022-11-17","excerpt":"Bibliometric evaluation of cancer research productivity across Arab countries between 2005 and 2019.","venue":"Journal of the Egyptian Public Health Association","article_type":"Journal Article","topics":"Public health","paperurl":"https://doi.org/10.1186/s42506-022-00120-6","pubmed":"https://pubmed.ncbi.nlm.nih.gov/36385361/","citation":"Machaalani M, El Masri J, El Ayoubi LM, Matar B. Cancer research activity in the Arab world: a 15-year bibliometric analysis. J Egypt Public Health Assoc. 2022;97(1):26. doi:10.1186/s42506-022-00120-6.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2024-01-05-tert-promoter-mutations-race-sex.md","url":"/publications/2024-01-05-tert-promoter-mutations-race-sex/","title":"TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type","fields":{ "title":"TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type","date":"2024-01-05","excerpt":"Genomic study defining differences in TERT promoter mutation prevalence across racial and sex-based groups and cancer types.","venue":"The Oncologist","article_type":"Journal Article","topics":"Cancer genomics","paperurl":"https://doi.org/10.1093/oncolo/oyad208","pubmed":"https://pubmed.ncbi.nlm.nih.gov/37462445/","citation":"El Zarif T†, Machaalani M†, Nawfal R†, Nassar AH, Xie W, Choueiri TK, Pomerantz M. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. Oncologist. 2024;29(1):8-14. doi:10.1093/oncolo/oyad208. †Equal contribution","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2024-10-03-liquid-biopsy-rcc-oncologist.md","url":"/publications/2024-10-03-liquid-biopsy-rcc/","title":"Liquid biopsy in renal cell carcinoma","fields":{ "title":"Liquid biopsy in renal cell carcinoma","date":"2024-10-03","excerpt":"Expert commentary on the prognostic significance of circulating tumor DNA in renal cell carcinoma.","venue":"The Oncologist","article_type":"Journal Article","topics":"Renal cell carcinoma, Biomarkers","paperurl":"https://doi.org/10.1093/oncolo/oyae230","pubmed":"https://pubmed.ncbi.nlm.nih.gov/39187381/","citation":"Machaalani M, Eid M, Semaan K, El Hajj Chehade R, Nawfal R, Baca SC, Choueiri TK. Liquid biopsy in renal cell carcinoma. Oncologist. 2024;29(10):821-823. doi:10.1093/oncolo/oyae230.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-02-01-nk-cell-dysfunction-ccrcc.md","url":"/publications/2025-02-01-nk-cell-dysfunction-ccrcc/","title":"Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes","fields":{ "title":"Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes","date":"2025-02-01","excerpt":"Single-cell and functional immunogenomic analysis identifying progressive tumor-resident NK cell dysfunction as a predictor of poor outcomes in advanced clear-cell renal cell carcinoma.","venue":"ESMO Open","article_type":"Journal Article","topics":"Renal cell carcinoma","paperurl":"https://doi.org/10.1016/j.esmoop.2024.104105","pubmed":"https://pubmed.ncbi.nlm.nih.gov/39813824/","citation":"Xu W, Birch G, Melki A, Moritz V, Bharadwaj M, Schindler NR, Labaki C, Saliby RM, Dinh K, Horst JT, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee GS-M, Hurwitz M, McGregor BA, Hirsch MS, Shukla SA, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open. 2025;10(2):104105. doi:10.1016/j.esmoop.2024.104105.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-02-10-axl-signaling-review.md","url":"/publications/2025-02-10-axl-signaling-review/","title":"AXL signaling in cancer: from molecular insights to targeted therapies","fields":{ "title":"AXL signaling in cancer: from molecular insights to targeted therapies","date":"2025-02-10","excerpt":"Comprehensive review of AXL receptor tyrosine kinase signaling, therapeutic targeting strategies, and resistance mechanisms across cancer types.","venue":"Signal Transduction and Targeted Therapy","article_type":"Review","topics":"Targeted therapies","paperurl":"https://doi.org/10.1038/s41392-024-02121-7","pubmed":"https://pubmed.ncbi.nlm.nih.gov/39924521/","citation":"Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L, Machaalani M, Eid M, Singh RP, Choueiri TK, Pal S, Sabarwal A. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct Target Ther. 2025;10(1):37. doi:10.1038/s41392-024-02121-7.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-05-01-kim1-prognostic-rcc.md","url":"/publications/2025-05-01-kim1-prognostic-rcc/","title":"KIM-1 as a prognostic marker in renal cell carcinoma","fields":{ "title":"KIM-1 as a prognostic marker in renal cell carcinoma","date":"2025-05-01","excerpt":"Review and clinical perspective highlighting KIM-1 as a promising noninvasive prognostic biomarker in renal cell carcinoma.","venue":"European Urology Focus","article_type":"Journal Article","topics":"Renal cell carcinoma, Biomarkers","paperurl":"https://doi.org/10.1016/j.euf.2025.06.012","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40619332/","citation":"Steiner C†, Machaalani M†, Bonventre JV, McDermott DF, Choueiri TK, Xu W. KIM-1 as a prognostic marker in renal cell carcinoma. Eur Urol Focus. 2025;11(3):432-435. doi:10.1016/j.euf.2025.06.012. †Equal contribution.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-06-02-ici-preexisting-neurologic-autoimmune.md","url":"/publications/2025-06-02-ici-preexisting-neurologic-autoimmune/","title":"Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders","fields":{ "title":"Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders","date":"2025-06-02","excerpt":"Multicenter retrospective cohort study evaluating the safety and clinical outcomes of immune checkpoint inhibitors in patients with preexisting autoimmune neurologic disorders.","venue":"JAMA Network Open","article_type":"Journal Article","topics":"Immunotherapy","paperurl":"https://doi.org/10.1001/jamanetworkopen.2025.13727","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40465294/","citation":"Fletcher K, Machaalani M, El Hajj Chehade R, Nassar AH, Nawfal R, Manos M, Menzies AM, Aboubakar-Nana F, Hasse JC, Pinato DJ, Johnson A, Olsson-Brown AC, Carlino MS, Malgieri A, Cortellini A, Singh A, Parikh K, Kim SY, Naqash AR, Long GV, Challa P, Choueiri TK, Sharon E, Shah S, Johnson DB. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open. 2025;8(6):e2513727. doi:10.1001/jamanetworkopen.2025.13727.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-08-01-comorbidity-immunotherapy-mrcc.md","url":"/publications/2025-08-01-comorbidity-immunotherapy-mrcc/","title":"Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma","fields":{ "title":"Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma","date":"2025-08-01","excerpt":"Multi-institutional study evaluating the impact of comorbidity burden on treatment outcomes and adverse events in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor–based combinations.","venue":"Clinical Genitourinary Cancer","article_type":"Journal Article","topics":"Renal cell carcinoma, Immunotherapy, Clinical outcomes","paperurl":"https://doi.org/10.1016/j.clgc.2025.102385","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40615325/","citation":"Yekeduz E, Zarba M, Saad E, El Hajj Chehade R, Eid M, Saliby RM, Steiner C, Machaalani M, Nawfal R, Semaan K, Ürün Y, Heng DYC, Choueiri TK. Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2025;23(4):102385. doi:10.1016/j.clgc.2025.102385.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-08-10-chromophobe-rcc-antitumor-immunity.md","url":"/publications/2025-08-10-chromophobe-rcc-antitumor-immunity/","title":"Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma","fields":{ "title":"Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma","date":"2025-08-10","excerpt":"Integrated single-cell and immunogenomic analysis defining the immune-depleted tumor microenvironment and impaired antitumor immunity in chromophobe renal cell carcinoma.","venue":"Journal of Clinical Oncology","article_type":"Journal Article","topics":"Renal cell carcinoma, Immunotherapy","paperurl":"https://doi.org/10.1200/JCO-25-00234","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40601888/","citation":"Labaki C, Saad E, Madsen KN, Hobeika C, Bi K, Alchoueiry M, Camp S, Hou Y, Bakouny Z, Matar S, El Ahmar N, Nyman J, Zhang L, Priolo C, Rout R, Daou M, Khabibullin D, Salem S, Schindler N, Saliby RM, Meli K, Wells C, Pimenta E, Takemura K, Marji J, Eid M, Sarlemi K, Xu J, Denize T, El Hajj Chehade R, Machaalani M, Nawfal R, Khattoun W, Saleh M, El Masri J, Haddad NR, Xu W, McGregor BA, Hirsch MS, Yilmaz R, Cheng DY, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2025;43(23):2639-2654. doi:10.1200/JCO-25-00234.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-08-18-axl-cmet-resistance-rcc.md","url":"/publications/2025-08-18-axl-cmet-resistance-rcc/","title":"Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress","fields":{ "title":"Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress","date":"2025-08-18","excerpt":"Preclinical study demonstrating that AXL inhibition overcomes c-Met–driven therapeutic resistance in renal cancer and promotes tumor cell death through enhanced oxidative stress.","venue":"Cancer Letters","article_type":"Journal Article","topics":"Renal cell carcinoma, Targeted therapies","paperurl":"https://doi.org/10.1016/j.canlet.2025.217984","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40829740/","citation":"Sabarwal A, Machaalani M, Rawat L, Wedel J, Tabasum S, Sasamoto Y, Buerger F, Ascione J, Eid M, Semaan K, Saad E, Yang Y, Lee D, Hodi FS, Freedman ML, Lee GSM, Balan M, Choueiri TK, Pal S. Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress. Cancer Lett. 2025;633:217984. doi:10.1016/j.canlet.2025.217984.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-11-04-mlh1-mmr-ici-ccrcc.md","url":"/publications/2025-11-04-mlh1-mmr-ici-ccrcc/","title":"MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma","fields":{ "title":"MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma","date":"2025-11-04","excerpt":"Genomic and immunohistochemical analysis identifying somatic MLH1 deficiency as a rare but robust predictor of exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma.","venue":"European Urology","article_type":"Journal Article","topics":"Renal cell carcinoma, Immunotherapy, Cancer genomics","paperurl":"https://doi.org/10.1016/j.eururo.2025.09.4162","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41193371/","citation":"Dawidek MT, Posada Calderon L, Shah PK, Mittal R, Agridag Ucpinar B, Bakouny Z, Meli K, Saad E, Saliby RM, Woo HJ, Khandwala YS, Eid M, Labaki C, Machaalani M, Coleman J, Russo P, Kotecha RR, Carlo MI, Akin O, Braun DA, Choueiri TK, Reznik E, Chen YB, Motzer RJ, Voss MH, Hakimi AA. MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma. Eur Urol. 2025 Nov 4:S0302-2838(25)04721-9. doi: 10.1016/j.eururo.2025.09.4162. Epub ahead of print. PMID: 41193371.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-11-14-slc1a1-nat-comm.md","url":"/publications/2025-11-14-slc1a1-nat-comm/","title":"The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs","fields":{ "title":"The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs","date":"2025-11-14","excerpt":"Mechanistic study identifying SLC1A1/EAAT3 as an epigenetically regulated metabolic dependency in clear cell renal cell carcinoma that sustains oncogenic metabolism, promotes immune exclusion, and drives metastatic progression.","venue":"Nature Communications","article_type":"Journal Article","topics":"Renal cell carcinoma, Cancer genomics, Cancer metabolism","paperurl":"https://doi.org/10.1038/s41467-025-64983-x","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41238532/","citation":"Grubb T, Koochaki P, Matar S, Ghandour F, Machaalani M, Saad E, Tang C, Reznik E, Khatun J, Salem C, Dubasik N, Orlando DA, Guenther MG, Parajuli G, Srivastava RM, Martinez SR, Coker JA, Kotecha RR, Hakimi AA, Asara JM, Chan TA, Vanharanta S, Stauffer SR, Kaelin WG Jr, Signoretti S, Choueiri TK, Chakraborty AA. The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs. Nat Commun. 2025;16(1):10012. doi:10.1038/s41467-025-64983-x.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2025-11-28-hif2-cachexia-rcc.md","url":"/publications/2025-11-28-hif2-cachexia-rcc/","title":"Targeting of HIF2-driven cachexia in kidney cancer","fields":{ "title":"Targeting of HIF2-driven cachexia in kidney cancer","date":"2025-11-28","excerpt":"Mechanistic and translational study demonstrating that HIF2-driven PTHLH mediates hypercalcemia and cachexia in clear cell renal cell carcinoma and is rapidly reversed by HIF2 inhibition.","venue":"Nature Medicine","article_type":"Journal Article","topics":"Renal cell carcinoma, Cancer metabolism, Targeted therapies","paperurl":"https://doi.org/10.1038/s41591-025-04054-2","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41315757/","citation":"Abu-Remaileh M, Stransky LA, Bhalerao N, Shirole NH, Jiang Q, Saad E, Machaalani M, Vigeant SM, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri TK, Pitarresi JR, Carr SA, Udeshi ND, Kaelin WG Jr. Targeting of HIF2-driven cachexia in kidney cancer. Nat Med. 2026 Jan;32(1):245-257. doi: 10.1038/s41591-025-04054-2. Epub 2025 Nov 28. Erratum in: Nat Med. 2026 Feb;32(2):766. doi: 10.1038/s41591-026-04236-6. PMID: 41315757; PMCID: PMC12823431.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-01-07-nature-medicine-smadcam1-mrcc.md","url":"/publications/2026-01-07-nature-medicine-smadcam1-mrcc/","title":"Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma","fields":{ "title":"Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma","date":"2026-01-07","excerpt":"Evaluation of soluble MAdCAM-1 as a prognostic biomarker in metastatic renal cell carcinoma, linking clinical outcomes to gut microbiota composition and immune regulation across three independent clinical trials.","venue":"Nature Medicine","article_type":"Journal Article","topics":"Renal cell carcinoma, Biomarkers","paperurl":"https://doi.org/10.1038/s41591-025-04067-x","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41501493/","citation":"Alves Costa Silva C†, Machaalani M†, Saliby RM†, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, Vernerey D, Lee GS, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Albiges L. Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma. Nature Medicine. 2026. doi:10.1038/s41591-025-04067-x. †Equal contribution.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-01-12-clinical-cancer-research-nf2-merlin-rcc.md","url":"/publications/2026-01-12-clinical-cancer-research-nf2-merlin-rcc/","title":"Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2","fields":{ "title":"Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2","date":"2026-01-12","excerpt":"Integrated clinical, genomic, and transcriptomic analysis of renal cell carcinoma with NF2 biallelic loss and merlin protein deficiency, demonstrating an aggressive phenotype characterized by high proliferation, immune dysfunction, frequent cell-cycle and DNA damage–response alterations, and limited benefit from immunotherapy.","venue":"Clinical Cancer Research","article_type":"Journal Article","topics":"Renal cell carcinoma, Biomarkers, Cancer genomics","paperurl":"https://doi.org/10.1158/1078-0432.CCR-25-2871","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41524698/","citation":"Yekedüz E, Bian W, Siegmund SE, Machaalani M, El Masri J, Saleh M, Saad E, Ascione L, El Halabi R, Steiner C, Mourad P, Berg SA, McGregor B, Mantia C, Ravi P, Xu W, Hirsch MS, Choueiri TK, Serzan M. Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2. Clinical Cancer Research. 2026. doi:10.1158/1078-0432.CCR-25-2871.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-04-01-jnci-tdxd-breast-cancer.md","url":"/publications/2026-04-01-jnci-tdxd-breast-cancer/","title":"Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer","fields":{ "title":"Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer","date":"2026-04-01","excerpt":"Comprehensive clinical, genomic, and immune correlates of T-DXd outcomes in advanced breast cancer across two independent institutional cohorts.","venue":"Journal of the National Cancer Institute","article_type":"Journal Article","topics":"Biomarkers, Targeted therapies","paperurl":"https://doi.org/10.1093/jnci/djaf344","pubmed":"https://pubmed.ncbi.nlm.nih.gov/41418409/","citation":"Nassar AH, Bou Farhat E, Abushukair H, Alchoueiry M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri TK, Rakaee M, Busund LTR, Takabe Y, Lau SF, Rall K, Naqash AR, Jansen C, Wang X, Challa P, Tarantino P, Partridge AH, Tolaney SM, Kwiatkowski DJ, Winer EP. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. JNCI. 2026 Apr 1;118(4):669-679. doi: 10.1093/jnci/djaf344. PMID: 41418409.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-04-22-img-representation-asco.md","url":"/publications/2026-04-22-img-representation-asco/","title":"International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings","fields":{ "title":"International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings","date":"2026-04-22","excerpt":"Analysis of oral and invited faculty representation of international medical graduates at the ASCO Annual Meetings.","venue":"JCO Oncology Practice","article_type":"Journal Article","topics":"Public health","paperurl":"https://doi.org/10.1200/OP-25-00067","pubmed":"https://pubmed.ncbi.nlm.nih.gov/40577682/","citation":"Roy AM, Bakouny Z, Dizman N, Paul MA, Ozay ZI, Lal BM, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Xie W, Lee AJ, Choueiri TK. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings. JCO Oncol Pract. 2026 Apr;22(4):708-716. doi: 10.1200/OP-25-00067. Epub 2025 Jun 27. PMID: 40577682.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-04-28-nrco-hif2.md","url":"/publications/2026-04-28-nrco-hif2/","title":"The clinical landscape of HIF2α inhibitors in oncology","fields":{ "title":"The clinical landscape of HIF2α inhibitors in oncology","date":"2026-04-28","excerpt":"State-of-the-art review of HIF2α inhibition, highlighting the biological discoveries, structural breakthroughs, and clinical advances that established HIF2α inhibitors as a therapeutic strategy in kidney cancer and other hypoxia-driven malignancies.","venue":"Nature Reviews Clinical Oncology","article_type":"Review","topics":"Renal cell carcinoma, Targeted therapies","paperurl":"https://doi.org/10.1038/s41571-026-01145-y","pubmed":"https://pubmed.ncbi.nlm.nih.gov/42050152/","citation":"Saad E†, Machaalani M†, McDermott DF, Choueiri TK. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology. 2026. doi: 10.1038/s41571-026-01145-y. †Equal contribution.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-06-25-nat-med-histidine.md","url":"/publications/2026-06-25-nat-med-histidine/","title":"Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling","fields":{ "title":"Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling","date":"2026-06-25","excerpt":"Multi-cohort study integrating plasma metabolomics, metagenomics, and clinical data to identify metabolic determinants of immunotherapy outcomes, linking histidine with improved survival and long-chain fatty acids and succinate with worse outcomes across advanced cancer types.","venue":"Nature Medicine","article_type":"Journal Article","topics":"Immunotherapy, Cancer metabolism","paperurl":"https://doi.org/10.1038/s41591-026-04481-9","pubmed":"https://pubmed.ncbi.nlm.nih.gov/42350644/","citation":"Suissa D, Fidelle M, Reich E, Pham TN, Thomas S, Björk JR, Liu P, Zhao L, Kitaoka K, Piard E, Lebhar I, Tian AL, Thelemaque C, Alves Costa Silva C, Deutsch E, Loriot Y, Segata N, Piccinno G, Hospers GAP, Maleki Vareki S, Silverman MS, Lenehan JG, Bataille V, Boulate D, Kuznetsova T, Weersma RK, Messaoudene M, Durand S, van der Aalst CM, de Koning HJ, Schuler-Thurner B, de Vries IJM, Rafie E, Saliby RM, Machaalani M, Haferkamp S, Schilling B, Porcari S, Ciccarese C, Iacovelli R, Cremolini C, Choueiri TK, Elkrief A, Kroemer G, Heinzerling L, Chamoto K, Ianiro G, Routy B, Derosa L, Paragios N, Zitvogel L. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. Nature Medicine. 2026. doi: 10.1038/s41591-026-04481-9.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-08-06-oncologist-rcc-lag3.md","url":"/publications/2026-08-06-oncologist-rcc-lag3/","title":"Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma","fields":{ "title":"Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma","date":"2026-08-06","excerpt":"Multi-modal analysis of DNA and RNA sequencing data from patients with renal cell carcinoma treated with first-line immunotherapy, identifying molecular and immune correlates of LAG-3 expression and an association between higher LAG-3 expression and improved early real-world response.","venue":"The Oncologist","article_type":"Journal Article","topics":"Renal cell carcinoma, Immunotherapy, Biomarkers","paperurl":"https://doi.org/10.1093/oncolo/oyag317","pubmed":"https://pubmed.ncbi.nlm.nih.gov/42578740/","citation":"Dudipala H, Dugan AJ, Jariwala U, Ronski K, Mercer J, Saad E, El Masri J, Machaalani M, Saleh M, Viets Layng K, Yu Y, Signoretti S, Braun D, Pal SK, Choueiri TK, McKay RR. Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma. The Oncologist. 2026;31(9):oyag317. doi: 10.1093/oncolo/oyag317.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-10-06-pharmacologic-hif2-inhibition-t-cell-function.md","url":"/publications/2026-10-06-pharmacologic-hif2-inhibition-t-cell-function/","title":"Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma","fields":{ "title":"Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma","date":"2026-10-06","excerpt":"In primary human T cells and patient samples, pharmacologic HIF-2α inhibition with belzutifan preserved proliferation, cytokine production, cytotoxicity, and activation states, supporting its immunologic safety in clear cell renal cell carcinoma.","venue":"The Journal of Clinical Investigation","article_type":"Journal Article","topics":"Renal cell carcinoma, Targeted therapies","paperurl":"https://doi.org/10.1172/JCI204613","pubmed":"https://pubmed.ncbi.nlm.nih.gov/42837196/","citation":"Madsen KN, Kashima S, Soulati H, Wirth L, Ito K, Yochum ZA, Moritz V, Walker J, Machaalani M, Ghali F, Kenney P, Adeniran A, Hurwitz M, Choueiri TK, Braun DA. Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma. J Clin Invest. 2026 Oct 6:e204613. doi: 10.1172/JCI204613.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_publications/2026-10-19-validation-intermediate-endpoints-real-world-data.md","url":"/publications/2026-10-19-validation-intermediate-endpoints-real-world-data/","title":"Novel framework for the validation of intermediate clinical endpoints in oncology real-world data","fields":{ "title":"Novel framework for the validation of intermediate clinical endpoints in oncology real-world data","date":"2026-10-19","excerpt":"A nationwide real-world study in metastatic breast cancer evaluates intermediate clinical endpoints against overall survival and proposes a framework for validating endpoints in oncology data.","venue":"Journal of the National Cancer Institute","article_type":"Journal Article","topics":"Clinical outcomes","paperurl":"https://doi.org/10.1093/jnci/djag390","pubmed":"https://pubmed.ncbi.nlm.nih.gov/42898006/","citation":"Labaki C, Bakouny Z, Sanglier T, Saad E, Valero Martin M, Tarantino P, Schmidt AL, Shim J, Braun DA, Bouquet F, Joyce M, Machaalani M, Van Allen EM, Xie W, Tolaney SM, Choueiri TK. Novel framework for the validation of intermediate clinical endpoints in oncology real-world data. J Natl Cancer Inst. 2026 Oct 19:djag390. doi: 10.1093/jnci/djag390.","intro":""},"body":"\n","media":{"gallery":[]}},{"path":"_talks/2021-07-14-cvd-covid-lebanon-oral.md","url":"/talks/2021-07-14-cvd-covid-lebanon-oral","title":"Perspectives on knowledge, precautionary behaviors, and psychological status of patients with cardiovascular diseases during the first wave of the COVID-19 pandemic in Lebanon","fields":{ "title":"Perspectives on knowledge, precautionary behaviors, and psychological status of patients with cardiovascular diseases during the first wave of the COVID-19 pandemic in Lebanon","date":"2021-07-14","excerpt":"
Discussing the knowledge, precautionary behaviors, and psychological impact of the first COVID-19 wave on patients with cardiovascular disease in Lebanon.
\n","venue":"Demystifying COVID-19: Lessons Learned and Future Opportunities conference","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Discussing the knowledge, precautionary behaviors, and psychological impact of the first COVID-19 wave on patients with cardiovascular disease in Lebanon.
\n","media":{"gallery":[]}},{"path":"_talks/2024-01-24-onclive-immune-signatures-oral.md","url":"/talks/2024-01-24-onclive-immune-signatures-oral","title":"Host immune signatures as predictors of response to immunotherapy-based regimens in metastatic renal cell carcinoma","fields":{ "title":"Host immune signatures as predictors of response to immunotherapy-based regimens in metastatic renal cell carcinoma","date":"2024-01-24","excerpt":"
Presenting work evaluating host immune gene-expression signatures as predictors of response to ICI-based regimens in metastatic RCC.
\n","venue":"OncLive National Fellows Forum: Genitourinary Cancers 2024","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Presenting work evaluating host immune gene-expression signatures as predictors of response to ICI-based regimens in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_talks/2024-05-24-asco-erbb2-urothelial-poster.md","url":"/talks/2024-05-24-asco-erbb2-urothelial-poster","title":"ERBB2 mutations and association with molecular phenotype in urothelial carcinoma","fields":{ "title":"ERBB2 mutations and association with molecular phenotype in urothelial carcinoma","date":"2024-05-24","excerpt":"
Evaluation of ERBB2 mutations and their association with molecular phenotypes in urothelial carcinoma.
Evaluation of ERBB2 mutations and their association with molecular phenotypes in urothelial carcinoma.
\n","media":{"gallery":[]}},{"path":"_talks/2024-07-11-kcrs-axl-cmet-poster.md","url":"/talks/2024-07-11-kcrs-axl-cmet-poster","title":"Inhibition of AXL along with c-Met overcomes resistance development in renal cell carcinoma","fields":{ "title":"Inhibition of AXL along with c-Met overcomes resistance development in renal cell carcinoma","date":"2024-07-11","excerpt":"
Poster on dual AXL and c-Met inhibition as a strategy to overcome therapeutic resistance in RCC.
\n","venue":"Kidney Cancer Research Symposium 2024","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Poster on dual AXL and c-Met inhibition as a strategy to overcome therapeutic resistance in RCC.
\n","media":{"gallery":[]}},{"path":"_talks/2024-09-14-esmo-erbb2-amplifications-poster.md","url":"/talks/2024-09-14-esmo-erbb2-amplifications-poster","title":"ERBB2 amplifications across sex, race, and cancer types","fields":{ "title":"ERBB2 amplifications across sex, race, and cancer types","date":"2024-09-14","excerpt":"
Analysis of ERBB2 amplification patterns across sex, race, and multiple cancer types.
\n","venue":"ESMO Congress 2024","article_type":"","topics":"","paperurl":"https://doi.org/10.1016/j.annonc.2024.08.2181","pubmed":"","citation":"","intro":""},"body":"
Analysis of ERBB2 amplification patterns across sex, race, and multiple cancer types.
\n","media":{"gallery":[]}},{"path":"_talks/2025-02-18-asco-gu-kim1-javelin-poster.md","url":"/talks/2025-02-18-asco-gu-kim1-javelin-poster","title":"KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101","fields":{ "title":"KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101","date":"2025-02-18","excerpt":"
Evaluation of circulating kidney injury molecule-1 (KIM-1) as a biomarker in metastatic RCC based on a post-hoc analysis of JAVELIN Renal 101.
Evaluation of circulating kidney injury molecule-1 (KIM-1) as a biomarker in metastatic RCC based on a post-hoc analysis of JAVELIN Renal 101.
\n","media":{"gallery":[]}},{"path":"_talks/2025-02-25-onclive-kim1-oral.md","url":"/talks/2025-02-25-onclive-kim1-oral","title":"KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101","fields":{ "title":"KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101","date":"2025-02-25","excerpt":"
Post-hoc analysis of JAVELIN Renal 101 evaluating circulating KIM-1 in metastatic RCC.
\n","venue":"OncLive National Fellows Forum: Genitourinary Cancers 2025","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Post-hoc analysis of JAVELIN Renal 101 evaluating circulating KIM-1 in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_talks/2025-05-22-sitc-biomarkers-oral.md","url":"/talks/2025-05-22-sitc-biomarkers-oral","title":"Implementing Biomarkers of Immunotherapy for Genitourinary Cancers","fields":{ "title":"Implementing Biomarkers of Immunotherapy for Genitourinary Cancers","date":"2025-05-22","excerpt":"
Invited talk at the Society for Immunotherapy of Cancer (SITC) Leveraging Biomarkers to Accelerate IO Drug Development Workshop, focused on practical implementation of immunotherapy biomarkers in genitourinary cancers.
\n","venue":"SITC Leveraging Biomarkers to Accelerate IO Drug Development Workshop","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Invited talk at the Society for Immunotherapy of Cancer (SITC) Leveraging Biomarkers to Accelerate IO Drug Development Workshop, focused on practical implementation of immunotherapy biomarkers in genitourinary cancers.
\n","media":{"gallery":[]}},{"path":"_talks/2025-05-28-asco-kim1-integrative-poster.md","url":"/talks/2025-05-28-asco-kim1-integrative-poster","title":"Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC","fields":{ "title":"Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC","date":"2025-05-28","excerpt":"
Poster detailing integrative clinical, genomic, and transcriptomic profiling of circulating KIM-1 in metastatic RCC.
Poster detailing integrative clinical, genomic, and transcriptomic profiling of circulating KIM-1 in metastatic RCC.
\n","media":{"gallery":[]}},{"path":"_talks/2025-07-18-kcrs-kim1-integrative-oral.md","url":"/talks/2025-07-18-kcrs-kim1-integrative-oral","title":"Integrative clinical, genomic, transcriptomic, and immunopathologic characterization of circulating KIM-1","fields":{ "title":"Integrative clinical, genomic, transcriptomic, and immunopathologic characterization of circulating KIM-1","date":"2025-07-18","excerpt":"
Presenting an integrative analysis of circulating kidney injury molecule-1 (KIM-1) in patients with metastatic renal cell carcinoma.
\n","venue":"Kidney Cancer Research Summit (KCRS) 2025","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"
Presenting an integrative analysis of circulating kidney injury molecule-1 (KIM-1) in patients with metastatic renal cell carcinoma.
\n","media":{"gallery":[]}},{"path":"_talks/2025-09-07-sitc-irae-adc-poster.md","url":"/talks/2025-09-07-sitc-irae-adc-poster","title":"Pan-tumor multicenter study of the impact of prior immune-related adverse events (irAEs) on safety and efficacy of subsequent antibody-drug conjugate (ADC)","fields":{ "title":"Pan-tumor multicenter study of the impact of prior immune-related adverse events (irAEs) on safety and efficacy of subsequent antibody-drug conjugate (ADC)","date":"2025-09-07","excerpt":"
Poster showing that prior irAEs during ICI therapy were associated with increased ADC toxicity across tumor types.
\n","venue":"Society for Immunotherapy of Cancer (SITC) annual meeting 2025","article_type":"","topics":"","paperurl":"https://jitc.bmj.com/content/13/Suppl_2/A454","pubmed":"","citation":"","intro":""},"body":"
Poster showing that prior irAEs during ICI therapy were associated with increased ADC toxicity across tumor types.
\n","media":{"gallery":[]}},{"path":"_talks/2025-10-17-madcam1-esmo-oral.md","url":"/talks/2025-10-17-madcam1-esmo-oral","title":"Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma: results from three independent clinical trials","fields":{ "title":"Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma: results from three independent clinical trials","date":"2025-10-17","excerpt":"
Evaluating soluble mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) as a prognostic biomarker in metastatic renal cell carcinoma across three independent clinical trials.
\n","venue":"ESMO Congress 2025","article_type":"","topics":"","paperurl":"https://doi.org/10.1016/j.annonc.2025.08.3215","pubmed":"","citation":"","intro":""},"body":"
Evaluating soluble mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) as a prognostic biomarker in metastatic renal cell carcinoma across three independent clinical trials.
\n","media":{"gallery":[]}},{"path":"_talks/2026-02-28-rwe-surrogates-gu-asco.md","url":"/talks/2026-02-28-rwe-surrogates-gu-asco","title":"Real-world endpoints as surrogates for overall survival in metastatic bladder cancer","fields":{ "title":"Real-world endpoints as surrogates for overall survival in metastatic bladder cancer","date":"2026-02-28","excerpt":"
Evaluating whether real-world endpoints can serve as surrogate markers for overall survival in metastatic bladder cancer using a large real-world cohort.
Evaluating whether real-world endpoints can serve as surrogate markers for overall survival in metastatic bladder cancer using a large real-world cohort.
\n","media":{"gallery":[]}},{"path":"_talks/2026-06-01-multiaxis-asco.md","url":"/talks/2026-06-01-multiaxis-asco","title":"A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma","fields":{ "title":"A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma","date":"2026-06-01","excerpt":"
Evaluating whether integrating KIM-1 and MAdCAM-1 into a composite risk score improves risk stratification beyond either biomarker alone and beyond IMDC criteria in metastatic renal carcinoma.
Evaluating whether integrating KIM-1 and MAdCAM-1 into a composite risk score improves risk stratification beyond either biomarker alone and beyond IMDC criteria in metastatic renal carcinoma.
![\"Portrait](\"/images/Machaalani_Marc_square.jpg\")
![](\"/images/500x300.png\")
","venue":"","article_type":"","topics":"","paperurl":"","pubmed":"","citation":"","intro":""},"body":"